Dynavax Technologies Corporation
Dynavax Technologies — Proxy Contest (May 2025)
14 slides from Dynavax Technologies's proxy contest presentation, May 19, 2025
Slide 1: Adjuvant-Enhanced Pipeline
Adjuvant-Enhanced Pipeline May 2025 Presented by
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation and any of the information contained herein (this is for discussion and general informational purposes only. This Presentation does not have regard for the specific investment objective, financial situation, suitability, or the particular need of any specific perso
Slide 3: Key Points
Key Points adjuvant, CpG 1018, provides a distinctive competitive edge that will lower development risk and ensure pipeline success. CpG 1018 does not improve the chances of successful development and commercialization.
Slide 4: Overview of Adjuvants and Vaccines
Overview of Adjuvants and Vaccines An adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better. 1 Dynavax was founded in 1996 on the basis of using proprietary immunostimulatory s
Slide 5: DVAX S-1 filed in 2003
1 DVAX S-1 filed in 2003 As early as 2003, Dynavax was already attempting to specifically 2 leverage CpG 1018 (aka 1018 ISS) to develop drugs for: Ragweed allergy HBV prophylaxis Asthma Non- Other similar ISS adjuvants were also being developed for: Innate immunity Grass allergy HBV immunotherapy Rh
Slide 6: After 20+ Years Of Trying, DVAX Only Has Heplisav to show for CpG 1018
After 20+ Years Of Trying, DVAX Only Has Heplisav to show for CpG 1018 CpG 1018 has already been tried in at least a dozen unique indications across over 40k patients and over two decades Since 2004 Many unique indications not comprehensive 40k+ patients NCT Number Start Date Study Status Conditions
Slide 7: The CpG 1018 Value Opportunity Has Already Proven to Be Highly Uncertain
The CpG 1018 Value Opportunity Has Already Proven to Be Highly Uncertain After 20+ years, CpG 1018 is used in only one FDA-approved vaccine The current Board has only overseen failures in pipeline development: x It failed to win an indication for Heplisav for hemodialysis after 20 years of developme
Slide 8: DVAX Has Tried Many Times to Develop a Flu Vaccine, Including with CpG 1018
DVAX Has Tried Many Times to Develop a Flu Vaccine, Including with CpG 1018 2003 DVAX S-1 2003 1 2010 2 2020 3 2025 This time is different? 1 https://www.fiercebiotech.com/biotech/dynavax-initiates-first-human-trial-universal-flu-vaccine-program 2 https://www.globenewswire.com/news-release/2020/07/1
Slide 9: Even Management Acknowledges Vaccine Development is Unpredictable
Even Management Acknowledges Vaccine Development is Unpredictable When asked if the Tdap program discontinuation provided any read-throughs to other vaccine programs, management acknowledged there were none even though this program also leveraged CpG 1018. -- from those results that you -- that perh
Slide 10: Dynavax has yet to offer a clear explanation for why another vaccine asset will work
Dynavax has yet to offer a clear explanation for why acquiring or developing another vaccine asset will work now, given its lack of success to date. e growth 1 20 years ago for the pandemic flu vaccine is the best risk-adjusted strategy available today. Increasing distractions from the still-unprodu
Slide 11: Deep Track Sees a Path to Meaningful Value Creation
Deep Track Sees a Path to Meaningful Value Creation A superior risk- 1 repurchase shares: indicative value of ~$33 per share in 2030 Step 1: Confirm Strategy Step 2: Capital Allocation Step 3: Lower Share Count Committed focus on Heplisav growth Return excess cash to shareholders Increase per-share
Slide 12: Deep Track Sees a Path to Meaningful Value Creation (cont.)
Deep Track Sees a Path to Meaningful Value Creation (cont.) THE MATH 1. Heplisav Valuation Projection 2030 consensus sales: $600M $33/share? Valuation multiple: 3.0x current year sales 1 (in line with current 2.7x valuation ) Assuming DVAX share count stays at 120M, and 3 x $600M = $1.8B Heplisav is
Slide 13: Additional Information: Vote the WHITE Proxy Card
Additional Information Vote the WHITE Proxy Card to Refocus Dynavax PROTECT YOUR INVESTMENT IN DYNAVAX candidates Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel on the WHITE proxy card Please visit www.RefocusDVAX.com for additional materials, information and voting instructions 13
Slide 14: REFOCUS
REFOCUS DYN2@VAX